Clinical Trial Update: Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of mazindol extended release (NLS-2) for narcolepsy and related daytime sleepiness has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataplexy Narcolepsy
• Excessive Daytime Sleepiness
• Narcolepsy

Drugs mentioned

• NLS-2 (Mazindol Extended Release) (mazindol extended release)

Snippet

Sponsor: NLS Pharmaceutics | Conditions: Narcolepsy, Excessive Daytime Sleepiness | Phase 2 | Status: COMPLETED